Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiazofurine

Drug Profile

Tiazofurine

Alternative Names: CI 909; CPD 5825; ICN 5825; NSC 286193; Riboxamide; Tiazofurin; Tiazole

Latest Information Update: 19 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Amides; Cytostatics; Ribonucleosides; Small molecules; Thiazoles
  • Mechanism of Action Immunomodulators; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Multiple myeloma; Myeloid leukaemia; Ovarian cancer

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 16 Jun 2003 Suspended - Phase-I for Multiple myeloma in Russia (IV)
  • 16 Jun 2003 Suspended - Phase-II for Ovarian cancer in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top